

# Identification of a mutational signature of dietary acrylamide in renal cancer genomes

*Kim M. Smits<sup>1</sup>, François Virard<sup>2,3</sup>, Bérénice Chavanel<sup>2</sup>, Sergey Senkin<sup>4</sup>, Vincent Cahais<sup>2</sup>, Claire Renard<sup>2</sup>, Kim Lommen<sup>1</sup>, Jaleesa van de Meer<sup>1</sup>, Marie-Pierre Cros<sup>2</sup>, Jeroen van de Pol<sup>5</sup>, Maria Zhivagui<sup>6</sup>, Behnoush Abedi-Ardekani<sup>4</sup>, Frederick A. Beland<sup>7</sup>, Michael Korenjak<sup>2</sup>, Leo J. Schouten<sup>5</sup>, Jiri Zavadil<sup>2\*</sup>*

<sup>1</sup> Maastricht University, Department of Pathology, Maastricht, The Netherlands

<sup>2</sup> International Agency for Research on Cancer WHO, Epigenomics and Mechanisms Branch, Lyon, France

<sup>3</sup> University Claude Bernard Lyon 1 INSERM U1052–CNRS UMR5286, Cancer Research Center, Centre Léon Bérard, Lyon, France

<sup>4</sup> International Agency for Research on Cancer WHO, Genomic Epidemiology Branch, Lyon, France

<sup>5</sup> Maastricht University, Department of Epidemiology, Maastricht, The Netherlands


<sup>6</sup> University of California San Diego, Moore's Cancer Center, La Jolla- CA, United States

<sup>7</sup> US Food and Drug Administration National Center for Toxicological Research, Division of Biochemical Toxicology, Jefferson, AR, United States

International Agency  
for Research on Cancer





zavadilj@iacr.who.int  
(\*presenter)



# Introduction & Background

- Acrylamide (ACR) forms in heated starchy and other foods and in the tobacco smoke
- Probable human carcinogen (IARC Group 2A)
- ACR and its reactive metabolite glycidamide (GA) - high priority compounds for IARC Monograph evaluation
- EGM previously discovered mutational signature SBS\_GA (Zhivagui M et al, 2019, PMID 30846532)
- SBS\_GA was found operative in 30% of ~1,600 ICGC PCAWG tumour genomes (19 human tumour types, 14 organs)
- Clear-cell renal cell carcinomas (ccRCCs) were markedly enriched for SBS\_GA (70% of 111 samples)




# Introduction & Background

- The ccRCC findings were consistent with our re-analysis of epidemiological studies indicating elevated non-significant risk associated with dietary ACR in never smokers
- ACR/GA mutational signature has not yet been specifically linked to ACR exposure history

# Hypothesis

- Exposure to dietary ACR/GA leads to dose-dependent genome-wide mutagenesis underlying ccRCC development



# Specific Aims

- Determine SBS\_GA in ccRCC and its correlation with documented dietary ACR intake

# Strategy & Design



- ccRCCs of never-smokers from the Netherlands Cohort Study on Diet and Cancer (NLCS)
- Compare low vs. high dietary ACR intake groups
- Whole-genome sequencing of macro-dissected FFPE material
- Innovative mutational signature analysis (extraction coupled with per-sample attribution)

## Netherlands Cohort Study on Diet and Cancer


120,852 subjects  
(birth years 1961-1931, 55-69 yrs old)  
204 municipalities  
Food frequency questionnaire:

- dietary habits (150 items)
- other risk factors


Cancer follow up >20 years  
480 cases of renal cancer  
235 available in tumor blocks



FFPE ccRCC



Mutational signature analysis




WGS Illumina  
NovaSeq 6000  
150 PE  
30-50x



# Results


- 5 *de novo* signatures identified, including at least one specific for FFPE-related artefacts
- No exposure-group signature enrichment was observed

## De novo signatures




FFPE sig

## Signature distribution




# Results

- 3 expected endogenous COSMIC signatures identified: SBS1, SBS5, SBS40
- No exposure-group signature enrichment was observed



# Results

- Signature SBS\_GA is found enriched in the high ACR exposure group (2-fold)
- SBS\_GA levels can discriminate the exposure groups
- No correlation with sex, age, alcohol or BMI has been observed





# Conclusions

- Our study reveals that the SBS\_GA signature enrichment in renal tumors of patients with documented ACR intake history, suggesting contributing effects of dietary ACR
- The findings may have important implications for the planned IARC Monographs evaluation of ACR and GA, and for cancer prevention aimed at the reduction of human exposure to ACR
- The study should be extended to a larger sample set and to other cancers sites

## References

- Hogervorst JG et al, Am J Clin Nutr, 2008
- Graff RE et al, CEBP, 2018
- Zhivagui M et al, Genome Res 2019
- Marques MM et al, IARC Monographs Priorities Group Lancet Oncol, 2019
- Barupal DK et al, Environ Int, 2021
- Senkin S, BMC Informatics, 2021
- Smits KM et al, 2024, Forthcoming

## Acknowledgements

Funding: INCa-INSERM Plan Cancer 2015; WCRF International, Grant No. SG\_2020\_089



# Key take-home message

- Dietary acrylamide generates a specific mutational signature in human kidneys, via the mutagenic effects of glycidamide, its reactive metabolite. This signature contributes to the mutational landscapes of renal tumors and it reflects the past acrylamide intake levels.